Cara Therapeutics Shares Eye New 1.5-Yr High on Po
Post# of 38
(Total Views: 733)
Posted On: 03/28/2017 9:33:08 AM
Cara Therapeutics Shares Eye New 1.5-Yr High on Positive Results in Part A of Phase 2/3 Trial For Uremic Pruritus
BY Midnight Trader
— 7:27 AM ET 03/28/2017
07:27 AM EDT, 03/28/2017 (MT Newswires) -- Shares of Cara Therapeutics ( CARA
Loading...
Loading...
) were rallying pre-market Tuesday after the biopharmaceutical firm reported positive top-line data from part A of a phase 2/3 trial evaluating I.V. CR845 in patients with uremic pruritus.
CARA was up 16%, on track to hit a new high since September 2015 if gains hold through regular trade. The stock has a 52-week range of $4.35 to $19.44.
The data showed that the treatment met both primary and secondary endpoints as it reduced itching and demonstrated an improved quality of life in dialysis patients suffering from uremic pruritus.
Uremic pruritus is described as an intractable and debilitating systemic itch condition that is highly prevalent in patients with chronic kidney disease, for which there are no approved therapies in the US.
Looking ahead, Cara Therapeutics ( CARA
Loading...
Loading...
) said it plans to meet with the Food and Drug Administration to finalize the trial design of the phase 2/3 study and to begin patient recruitment later in 2017.
Price: 21.00, Change: +2.85, Percent Change: +15.70
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
BY Midnight Trader
— 7:27 AM ET 03/28/2017
07:27 AM EDT, 03/28/2017 (MT Newswires) -- Shares of Cara Therapeutics ( CARA
Loading...
Loading...
) were rallying pre-market Tuesday after the biopharmaceutical firm reported positive top-line data from part A of a phase 2/3 trial evaluating I.V. CR845 in patients with uremic pruritus.
CARA was up 16%, on track to hit a new high since September 2015 if gains hold through regular trade. The stock has a 52-week range of $4.35 to $19.44.
The data showed that the treatment met both primary and secondary endpoints as it reduced itching and demonstrated an improved quality of life in dialysis patients suffering from uremic pruritus.
Uremic pruritus is described as an intractable and debilitating systemic itch condition that is highly prevalent in patients with chronic kidney disease, for which there are no approved therapies in the US.
Looking ahead, Cara Therapeutics ( CARA
Loading...
Loading...
) said it plans to meet with the Food and Drug Administration to finalize the trial design of the phase 2/3 study and to begin patient recruitment later in 2017.
Price: 21.00, Change: +2.85, Percent Change: +15.70
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
(0)
(0)